Article PDF
Avoid common mistakes on your manuscript.
References
Parfrey PS, Griffiths SM, Barrett BJ et al (1989) Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 320:143–149
Rudnick MR, Goldfarb S, Wexler L et al (1995) Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int 47:254–261
Scheller B, Hennen B, Thünenkötter T et al (1999) Influence of X-ray contrast media on rheological properties after coronary angiography. Thromb Res 96:253–260
Idee JM, Lancelot E, Pines E, Corot C (2004) Prophylaxis of iodinated contrast media-induced nephropathy: a pharmacological point of view. Invest Radiol 39:155–170
Reinecke H, Fobker M, Wellmann J, Becke B, Fleiter J, Heitmeyer C, Breithardt G, Hense HW, Schaefer RM (2007) A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: The Dialysis-versus-Diuresis-(DVD)-Trial. Clin Res Cardiol 96:130–139
Tepel M, van der Giet M, Schwarzfeld C et al (2000) Prevention of radiographic- contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343:180–184
Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ (2004) Prevention of radiocontrast nephropathy with Nacetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 43:1–9
Duong MH, Mackenzie TA, Malenka DJ (2005) N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Catheter Cardiovasc Interv 64:471–479
Kshirsagar AV, Poole C, Mottl A et al (2004) N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 15:761–769
Pannu N, Manns B, Lee H, Tonelli M (2004) Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 65:1366–1374
Pannu N, Wiebe N, Tonelli M (2006) Prophylaxis strategies for contrast-induced nephropathy. JAMA 295:2765– 2779
Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL (2006) N-Acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354:2773–2782
Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK (2004) The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15:407–410
Marenzi C, Marana I, Lauri G et al (2003) The prevention of radiocontrast agent-induced nephropathy by hemofiltration. N Engl J Med 349:1330–1340
Vogt B, Ferrari P, Schoenholzer C et al (2001) Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 111:692–698
Lehnert T, Keller E, Gondolf K et al (1998) Effects of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant 13:358–362
Scheller B, Hennen B, Pohl A, Schieffer H, Markwirth T (2001) Acute and subacute stent occlusion: risk-reduction by ionic contrast media. Eur Heart J 22:385–391
Sutton A, Finn P, Grech E et al (2001) Early and late reactions after the use of iopamidol 340, ioxaglate 320, and iodixanol 320 in cardiac catheterization. Am Heart J 141:677–683
Aspelin P, Aubry P, Fransson SG et al (2003) Nephrotoxic effects in highrisk patients undergoing angiography. N Engl J Med 348:491–499
Jo SH, Youn TJ, Koo BK et al (2006) Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography. The RECOVER study: a randomized controlled trial. J Am Coll Cardiol 48:924–930
Baker CS, Wragg A, Kumar S et al (2003) A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 41:2114–2118
Stone GW, McCullough PA, Tumlin JA et al, CONTRAST Investigators (2003) Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 290:2284–2291
Sharma SK, Annapoorna K (2005) Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials. Cath Card Int 65:386–393
Solomon R, Werner C, Mann D, D'Elia J, Silva P (1994) Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331:1416–1420
Müller C, Bürkle G, Büttner HJ et al (2002) Prevention of contrast mediaassociated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162:329–336
Diaz-Sandoval LJ, Kosowsky BD, Losordo DW (2002) Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 89:356–358
Ochoa A, Isayenko Y, Pellizzon G et al (2002) Abbreviated dosing of Nacetylcysteine prevents contrast induced acute renal failure after coronary angiography and intervention. Circulation 106(Suppl):II–136
Shyu KG, Cheng JJ, Kuan P (2002) Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 40:1383–1388
Efrati S, Dishy V, Averbukh M et al (2003) The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int 64:2182–2187
Kay J, Chow WH, Chan TM et al (2003) Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 289:553–558
MacNeill BD, Harding SA, Bazari H et al (2003) Prophylaxis of contrastinduced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv 60:458– 461
Miner SE, Dzavik V, Nguyen-Ho P et al (2004) N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J 148:690–695
Allaqaband S, Tumuluri R, Malik AM et al (2002) Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 57:279–283
Briguori C, Manganelli F, Scarpato P et al (2002) Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 40:298–303
Durham JD, Caputo C, Dokko J et al (2002) A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 62:2202–2207
Kahlon JP, Moser L, Rosman H et al (2002) Effectiveness of N-acetylcysteine for the prevention of radiocontrast- induced nephropathy: is the jury still out? Circulation 106:II–691
Vallero A, Cesano G, Pozzato M et al (2002) Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC). G Ital Nefrol 19:529–533
Boccalandro F, Amhad M, Smalling RW et al (2003) Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 58:336–341
El Mahmoud R, Le Feuvre C, Le Quan Sang KH et al (2003) Absence d’effet nephroprotecteur de l’acetylcysteine chez les patients avec insuffisance renale chronique explores par coronarographie. Arch Mal Coeur 96:1157–1161
Loutrianakis E, Stella D, Hussain A et al (2003) Randomized comparison of fenoldopam and N-acetylcysteine to saline in the prevention of radio-contrast induced nephropathy. J Am Coll Cardiol 41(Suppl):327A
Oldemeyer JB, Biddle WP, Wurdeman RL et al (2003) Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 146:E23
Fung JW, Szeto CC, Chan WW et al (2004) Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis 43:801–808
Goldenberg I, Shechter M, Matetzky S et al (2004) Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J 25:212–218
Webb JG, Pate GE, Humphries KH et al (2004) A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 148:422–429
Azmus AD, Gottschall C, Manica A et al (2005) Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invasive Cardiol 17:80–84
Gomes VO, Poli de Figueredo CE, Caramori P, Lasevitch R, Bodanese LC, Araujo A, Rödel AP, Caramori AP, Brito FS Jr, Bezerra HG, Nery P, Brizolara A (2005) N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart 91:774–778
Huber W, Eckel F, Hennig M, Rosenbrock H, Wacker A, Saur D, Sennefelder A, Hennico R, Schenk C, Meining A, Schmelz R, Fritsch R, Weiss W, Hamar P, Heemann U, Schmid RM (2006) Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology 239:793–804
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scheller, B. How to protect from Contrast Media-induced nephropathy?. Clin Res Cardiol 96, 125–129 (2007). https://doi.org/10.1007/s00392-007-0486-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-007-0486-z